Aytu BioScience

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

Aytu BioScience is focused on delivering innovative healthcare solutions and products to improve patient lives and advance clinical care.

Aytu BioScience seeks to create the world's most advanced and distinguished life sciences company, one that discovered, develops, and invests in an ever-expanding suite of products and services.

Aytu BioScience has been recognized with various awards including the Frost & Sullivan Global Healthcare Innovation Award, the American Business Award for best new product, and the Global Health and Pharma Award for best new product innovation.